PCSK9 and urolithiasis: Similarly, MR analysis utilizing the IVW model (Supplementary Figure 5H) did not reveal any causal association between PCSK9 inhibitors and a reduced risk of urinary stones, with no statistically significant difference ([OR], 1.002; 95% [CI], 1.000-1.005, P=0.099).